Benzinga | Jul 14, 2021 09:06AM EDT

Medicenna Therapeutics Corp Highlights Publication Of Preclinical Data On MDNA109 In Frontiers in Immunology

TORONTO and HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced the peer-reviewed publication of preclinical data on MDNA109, the Company's IL-2 Superkine platform that forms the basis for MDNA11. The paper, which was published in Frontiers in Immunology, was independently authored by researchers at the University of Helsinki (Finland) and other institutions.